NCT00391248View on ClinicalTrials.gov

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

150 mg in a single daily dose, starting Day 1 through Day 22

Trial Locations (2)

L8V 1C3

Juravinski Cancer Centre, Hamilton

M5N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00391248 - Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) | Biotech Hunter | Biotech Hunter